Canine mammary gland tumors: risk factors and their epidemiological influence in Manizales-Colombia

Alejandro Clavijo-Maldonado1,4* Esp; Juan M. Pérez-Zapata2 M.Sc; Enio Ferreira3 Ph.D; Carlos Vargas-Hernandez4 Ph.D; Fredy A. Rivera-Páez1 Ph.D.

1Universidad de Caldas, Facultad de Ciencias Exactas y Naturales, Departamento de Ciencias Biológicas, Grupo de Investigación GEBIOME, Manizales, Colombia.
2Universidad de Caldas, Facultad de Ciencias Agropecuarias, Departamento de Salud Animal, Manizales, Colombia.
3Universidade Federal de Minas Gerais Departamento de Patologia, Geral, Instituto de Ciências Biológicas, Belo Horizonte, Minas Gerais, Brasil.
4Universidad Nacional de Colombia, Departamento de Física y Química, Propiedades Ópticas de Materiales, Manizales, Colombia.
*Correspondence: alejandrocmvz@misena.edu.co

ABSTRACT

Objective. To describe the prevalence of canine mammary gland tumors (CMT) in females in the municipality of Manizales-Colombia from 2014-2017. Materials and methods. A database of 15961 patients was consolidated. The variables analyzed were, breed, age, reproductive history, weight, diet type and clinical characterization of the tumor with the TNM (tumor-node-metastases) staging system. The statistical analysis include Pearson’s chi-squared test with Yates correction for continuity and Fisher’s exact test (p < 0.05), relative risk and odds ratios (CI95%) and Kaplan-Meier estimator for survival analysis. Results. The incidence in purebred dogs was 79.14%, with a peak at the average age of 9.3 years old. Pearson’s chi-squared test and the relative risk and odds ratios indicated a high risk for purebreds (p=0.019, 3.96/100, 1.64, respectively). Females of ages between 9 and 12 years old showed a 74% likelihood of developing a mammary tumor. No found significant relation to weight or reproductive stage but indeed a high association with homemade diet (p<0.001). The inguinal mammary pairs were the most affected (6.9%). The Kaplan-Meier estimate showed a higher survival of surgically-intervened patients, with 2013 days of survival after diagnosis with surgery compared to 1484 days without surgery. Conclusions. The study confirmed the relevance of risk factors, breed type, age, body condition and diet type in the mammary tumor presentation. Furthermore, it highlights the need for improving and integrating the veterinary diagnostic information systems, considering their importance in public health.

Keywords: Cancer; epidemiology; incidence; prevalence (Source: CAB).
RESUMEN

Objetivo. Describir la prevalencia del tumor mamario canino (TMC) en hembras en el municipio de Manizales-Colombia durante 2014-2017. Materiales y métodos. Se consolidó una base de datos de 15961 pacientes. Las variables analizadas fueron raza, edad, historia reproductiva, condición corporal, tipo de dieta, y caracterización clínica del tumor mediante el sistema de estadificación tumor-nódulo-metástasis (TNM). El análisis estadístico incluyó prueba de chi-cuadrado de Pearson con corrección de Yates, prueba exacta de Fisher (p<0.05), riesgo relativo, oportunidad relativa (IC95%) y análisis de supervivencia de Kaplan-Meier. Resultados. La incidencia en perros de razas puras fue 79.14%, con un pico promedio a la edad de 9.3 años. La prueba chi-cuadrado de Pearson, el riesgo y las oportunidades relativos mostraron un riesgo alto para razas puras (p=0.019, 3.96/100, 1.64, respectivamente). Hembras entre los 9 y 12 años mostraron una probabilidad del 74% de desarrollo de tumor mamario. No se encontró una relación significativa entre la masa corporal o estado reproductivo pero una elevada asociación con la dieta casera (p<0.001). Los pares inguinales mamarios fueron los más afectados (6.9%). La estimación de Kaplan-Meier mostró una alta supervivencia para pacientes intervenidas quirúrgicamente, con 1315 días después del diagnóstico con cirugía en comparación con 1484 días sin cirugía. Conclusiones. El estudio confirma la relevancia de los factores de riesgo: tipo de raza, edad, condición corporal y tipo de dieta en la presentación de tumor mamario. Además, se destaca la necesidad de mejorar e integrar los sistemas de información de diagnóstico veterinario, considerando su importancia en la salud pública.

Palabras clave: Cáncer; epidemiología; incidencia; prevalencia (Fuente: CAB).

INTRODUCTION

Canine mammary gland tumor (CMT) is one of the most common tumors in dogs (1) and one of the main causes of mortality, similarly, as occur in humans (2,3). In female dogs, 40% of tumors are of the mammary gland (4,5) and these are three times more frequent than in women (1,6). In particular, intact females are more susceptible (4,7,8,9,10,11).

Canine mammary tumors are the second most frequent type after skin tumors (12,13). There are several predisposing factors to the presentation of CMT. For instance, purebreds are more susceptible (9,10) and, among these, small breeds are more susceptible to CMT (7,10,14). Age-wise, the highest incidence of CMT is estimated from 8 to 10 years old (1,8,9,10,13,14,15,16).

Early sterilization greatly reduces the susceptibility of developing CMT (17) and increases the survival rate (7,14). Ovarian steroid hormones or exogenous products, such as medroxyprogesterone acetate, stimulate the proliferation of the mammary tissue and, consequently, increase the risk of CMT (8,17,18). Another relevant risk factor is excess weight and obesity, which markedly increase the risk of CMT (19). Although other authors have not found this association (20). Homemade diets rich in fat is another risk factor (8,19). Many of these risk factors are shared with humans, in particular, lifestyle, type of diet/obesity, and hormonal birth control therapies (21,22).

Although CMT is a relatively common disease, in several places the databases are not consolidated, represents a challenge for data retrieval (23). Many clinical records are incomplete, ambiguous, or do not indicate the definitive diagnosis or the length of survival of the patients (24). The main objective of this study was to describe the prevalence of CMT in females and males in the municipality of Manizales-Colombia from 2014-2017.

MATERIALS AND METHODS

Data retrieval. We consolidated a database from clinical records between 2014 and 2017 provided by eight veterinary care centers in the city of Manizales (Caldas, Colombia). Access to the clinical records was done with signed consent from the animal owners and/or veterinarians. The constructed database was filtered to establish four groups of patients: Group I: all patients reported from consultations. Group II: patients from group I with a clinical diagnosis. Group III: patients from group II with any type of tumor affection. Group IV: it includes patients
from group III with a mammary gland tumor. The variables analyzed in the females diagnosed with CMT were breed (25), and breed type (purebred or mixed-breed), age, weight, type of diet, reproductive stage, hormonal treatments, and clinical characterization of the tumor (type, size, number of affected mammary glands, affected location, and metastasis).

We estimated the rate of presentation of tumor pathologies each year and determined the most affected organ system, as well as the annual number of females diagnosed with CMT. The topographic classification was done based on the Classification of Disease for Oncology System (ICD-O) (26). We determined the disease prevalence according to breed, age, and weight (normal, overweight, or obese based on the breed). In dogs, overweight is considered being 15% more than the “optimal weight” (27,28) and obese when it exceeds 30% (29).

The clinical characterization of the tumors was determined based on the TNM staging system (30). The histopathological findings were adapted according to Cassali et al (31). The data were consolidated in a MS Excel® spreadsheet. We also searched the bank of histopathological slides and histopathological reports databases of the consulted veterinary attention centers. We made a photographic register with a Leica ICC50 HD camera system and analyzed the images with ImageJ software (Wayne Rasband, National Institutes of Health, USA). Finally, we confirmed by telephone, the survival time from the initial diagnosis and surgical procedure of the females.

Statistical analysis. The relationship between the variables breed, age, weight, type of diet, and reproductive stage was determined using Pearson’s chi-squared test with Yates correction and Fisher’s exact test for continuous data with p<0.05. We also estimated epidemiological indices including incidence rate (relative risk – RR) for the female population over six years old with a definitive diagnosis and odds ratio – OR with a confidence interval of 95% (CI95%). The RR was calculated as the total number of canine females per 100 females-years divided by the total number of diagnosed females. The OR was estimated using 2x2 tables for each the study variables. The data was consolidated in a MS Excel® spreadsheet and analyzed using the R statistical package v.3.5.3 (R Foundation for Statistical Computing, Vienna, Austria). The survival analysis was performed using the Kaplan-Meier estimator (p<0.05) with GraphPad Prism v.8.2.0 software (GraphPad Software Inc., San Diego, CA).

RESULTS

General prevalence. The consolidated database (2014-2017) allowed distributing the patients into four groups. Group I (n=20815); Group II (n=15961), 15258 canines; Group III, tumor alterations (n=403), female and male canines; Group IV, females with CMT diagnosis (n=139) (Table 1). We classified the data into 30 categories for each tumor alteration (ICD-O), in addition to a non-determined category. The general prevalence of the tumor alterations was 2.52% (403/15961). The most affected system during 2014-2017 was the mammary gland (code C50), 34.5%, followed by the skin (C44), 88 cases (21.8%). We found 139 alterations of the mammary gland that corresponded to CMT. We excluded those of different origin. The general prevalence of CMT was 0.87% (139/15961).

Prevalence by breed, age, and body condition. Purebreds were more affected (79.14%) compared to mixed-breeds (20.86%) (Table 2). The most affected breeds were French Poodle (24%), Pinscher (10%), Miniature Schnauzer, Cocker Spaniel, Beagle, and Labrador Retriever (Table 2). The mean age of the patients was 9.3 years old (SD= ±3.68) and the median was 10 years. The age range was Xmin 1year - Xmax 16 years. The most reported age ranges were 10 to 12 years old (n=24; 17.3%), followed by 7 to 9 years (n=21; 15.1%). Females older than 12 years (n=13; 9.4%), 4 to 6 years old (n=7; 5%) and less than 4 years old (n=6; 4.3%). We found that 48.9% (n=68) of the clinical records did not describe the age of the patient. Moreover, 75.5% (n=80) were patients with normal weight, 10.4% (n=11) were overweight, and 15 patients were obese (n=15; 14.1%). We did not include mixed-breeds (n=29).

Pearson’s chi-squared test with Yates’ correction for continuity showed a chi-squared value of 5.4287 (p=0.019) for breeds, indicating a positive relationship between breed and CMT. This result agrees with the breed-wise RR of 3.96/100-females, indicating a high risk (OR=1.64). Fisher’s test showed a strong relationship between CMT and age (p<0.001). The ages from 9 to 12 years showed the highest significant risk for CMT (OR 2.81). We did not find a significant relationship between body mass (weight) and the presence of CMT (p=0.051).
Table 1. Tumor alterations by organ system in canines of Manizales, Colombia from 2014-2017.

| Sitie                                      | Topographic Code (ICD-O) | Total (%) | Female (%) | Male (%) |
|--------------------------------------------|--------------------------|-----------|------------|----------|
| Tongue, UP                                  | C02                      | 1         | 0.2        | 1        | 0.2      |
| Mouth floor                                | C04                      | 1         | 0.2        | 0        | 1        |
| Mouth UP                                   | C06                      | 18        | 4.0        | 8        | 1.8      | 10       | 2.2      |
| Nasopharynx                                | C11                      | 2         | 0.4        | 1        | 0.2      | 1        | 0.2      |
| Small intestine                            | C17                      | 1         | 0.2        | 1        | 0.2      | 0        |          |
| Anus and anal canal                        | C21                      | 2         | 0.4        | 0        | 2        | 0.4      |          |
| Liver and intrahepatic ducts               | C22                      | 9         | 2.0        | 2        | 0.4      | 7        | 1.6      |
| Other digestive organs (intestine, GI)     | C26                      | 1         | 0.2        | 1        | 0.2      | 0        |          |
| Bronchi and Lung                            | C34                      | 1         | 0.2        | 1        | 0.2      | 0        |          |
| Heart, mediastinum, pleura                 | C38                      | 1         | 0.2        | 1        | 0.2      | 0        |          |
| Bones, joints, cartilage                   | C40                      | 1         | 0.2        | 1        | 0.2      | 0        |          |
| Bones, joints, cartilage, UP               | C41                      | 2         | 0.4        | 1        | 0.2      | 1        | 0.2      |
| Hematopoietic and reticuloendothelial system | C42                      | 3     | 0.7        | 1        | 0.2      | 2        | 0.4      |
| Spleen                                     | C42.2                    | 8         | 1.8        | 1        | 0.2      | 7        | 1.6      |
| Skin                                       | C44                      | 88        | 19.7       | 37       | 8.3      | 51       | 11.4     |
| Connective, subcutaneous and other tissue  | C49                      | 8         | 1.80       | 6        | 1.3      |          |          |
| Mammary gland                              | C50                      | 139       | 40.8       | 139      | 31.4     | 0        |          |
| Vulva                                      | C51                      | 1         | 0.2        | 1        | 0.2      | 0        |          |
| Vagina                                     | C52                      | 23        | 5.2        | 23       | 5.2      | 0        |          |
| Uterus                                     | C55                      | 1         | 0.2        | 1        | 0.2      | 0        |          |
| Ovaries                                    | C56                      | 1         | 0.2        | 1        | 0.2      | 0        |          |
| Penis                                       | C60                      | 25        | 5.6        | 0        | 25       | 5.6      |          |
| Prostate gland                             | C61                      | 4         | 0.9        | 0        | 4        | 0.9      |          |
| Testicles                                  | C62                      | 13        | 2.9        | 0        | 13       | 2.9      |          |
| Kidney                                     | C64                      | 2         | 0.4        | 1        | 0.2      | 1        | 0.2      |
| Eyes and annexes                           | C69                      | 5         | 1.1        | 1        | 0.2      | 4        | 0.9      |
| Brain                                      | C71                      | 2         | 0.4        | 1        | 0.2      | 1        | 0.2      |
| Thyroid gland                              | C73                      | 1         | 0.2        | 1        | 0.2      | 0        |          |
| Lymph nodes                                | C77                      | 1         | 0.2        | 0        | 1        | 0.2      |          |
| Unknown Primary Site                        | C80                      | 1         | 0.2        | 0        | 1        | 0.2      |          |
| Undetermined                               | ND                       | 37        | 8.3        | 26       | 5.8      | 11       | 2.5      |
| **Total**                                  |                          | 403       | 100        | 257      | 63.8     | 146      | 36.2     |

*aICD-O: Structure of the topographic code. Site=(C00), sub-site=(.0).

Table 2. Breed-wise morbidity from CMT in canines of Manizales, Colombia, according to the classification by Salt et al (25).

| Breed type (Kg) | Breed                      | Total cases | Proportion(%) |
|-----------------|----------------------------|-------------|---------------|
| I (< 6.5)       | Chihuahua                  | 1           | 1             |
|                 | Maltese                    | 1           | 1             |
|                 | Pinscher                   | 14          | 10            |
|                 | Yorkie                     | 1           | 1             |
|                 | Yorkshire Terrier          | 1           | 1             |
| **Total**       |                            | 21          | 15.1          |
| II (6.5 to < 9) | Jack Russell Terrier       | 1           | 1             |
|                 | Pekingese                  | 1           | 1             |
|                 | Miniature schnauzer        | 5           | 4             |
|                 | Shih Tzu                   | 2           | 1             |
| **Total**       |                            | 9           | 6.5           |
| III (9 to < 15) | French bulldog             | 2           | 1             |
|                 | Cocker Spaniel             | 5           | 4             |
|                 | Pug                        | 1           | 1             |
|                 | Beagle                     | 5           | 4             |
|                 | Boston terrier             | 1           | 1             |
|                 | Fox Terrier                | 1           | 1             |
|                 | French Poodle              | 34          | 24            |
| **Total**       |                            | 49          | 35.3          |
| IV (15 to < 30) | Basset Hound               | 3           | 2             |
|                 | English bulldog            | 2           | 2             |
|                 | Pit Bull                   | 4           | 3             |
| **Total**       |                            | 10          | 7.2           |
| V (30 to < 40)  | Golden Retriever           | 4           | 3             |
|                 | Labrador Retriever         | 6           | 4             |
|                 | German shepherd            | 4           | 3             |
|                 | Siberian Husky             | 4           | 3             |
| **Total**       |                            | 18          | 12.9          |
| VI (40+)        | Rottweiller                | 3           | 2             |
| **Total**       |                            | 3           | 2.2           |
| Other           | Mongrel                    | 29          | 21            |
| **Total**       |                            | 29          | 20.9          |
| **Total**       |                            | 139         | 100           |
The chi-squared test indicated a relationship between CMT and homemade food diet (p<0.001) and a RR=1.8 showed a high risk for this variable. We did not find a relationship for CMT and the reproductive stage (p=0.913), OR=1.47, indicating it is a non-significant risk factor. Although, this could be attributed to the few reports on the reproductive stage of the patients (Table 3).

Clinical aspects. Twenty-four clinical records provide reports of TNM staging the left mammary ridge being the most compromised. The inguinal pairs are the most affected (pair 5: 18.2% left and 15.6% right). For the variable diameter of the primary tumor (T) of the TNM staging system, we found that T1 (<3cm diameter) is the most reported with 38.46%, followed by T3 (3-5cm, 29.23%), and T2 (> 5cm, 20%). T4 (inflammatory carcinoma) comprises tumors adhered to the skin (6.15%), as well as non-fixed (4.62%) and 1.54% fixed to the muscle. Absence of compromise to the regional lymph node-LN (N) and distant metastasis (M) was 70.8% (N0, M0), N1 and M1 (29.2%) for both. The predominant Clinical Stage (CS) was CS-V (25%), followed by CS-I, CS-III, and CS-IV (20.8%), respectively, and CS-II, 12.5%.

Of the histopathological findings, 18% were benign neoplasia, non-determined (ND) hyperplasia, mammary adenoma, and fibroadenoma. On the other hand, 5% were malignant neoplasia, mammary carcinoma-ND, papillary carcinoma, tubular carcinoma, and mixed tumor carcinoma. Figure 1 shows histopathological diagnostic slides of some of the females included in this study. Unfortunately, 77% were CMT reports with no definitive histopathological diagnosis. Metastases to the lung and the LN were reported in 31% and 38% of cases, respectively.

The Kaplan-Meier curve indicated a higher survival of patients that were surgically intervened, showing a survival period of 2013 days after diagnosis with surgery compared to 1484 days without surgery. The survival period after surgery was 2005 days. We did not observe significant differences for both analyses (p=0.31 and 0.183, respectively) (Figure 2). The analysis of the clinical records was challenging, particularly due to incomplete records and unclear reports of the clinical findings.

### Table 3. Odds Ratio (OR) with a 95% confidence level (95%CI), probability and risk for patients diagnosed with CMT. Variables breed, age, weight, type of diet, reproductive stage.

| Category           | CMT          |          | OR     | 95% CI | Probability |
|--------------------|--------------|----------|--------|--------|-------------|
|                    | Diseased     | Healthy  | Total  |        |             |
| Breed              |              |          |        |        |             |
| Pure               | 103          | 233      | 336    | 1.64a  | 1.08-2.49   | 62%         |
| Mongrel            | 26           | 73       | 99     | 0.61b  | 0.40-0.92   | 38%         |
| Age (Years)        |              |          |        |        |             |
| 0-4                | 19           | 167      | 186    | 0.3b   | 0.16-0.56   | 23%         |
| 5-8                | 19           | 167      | 186    | 0.36b  | 0.18-0.71   | 26%         |
| 9-12               | 22           | 80       | 102    | 2.81b  | 1.42-5.58   | 74%         |
| ≥ 13               | 19           | 55       | 74     | 1.33c  | 0.59-3.03   | 57%         |
| Weight             |              |          |        |        |             |
| Normal             | 80           | 65       | 145    | 0.64c  | 0.39-1.03   | 39%         |
| Overweight / Obesity| 26          | 22       | 48     | 1.57c  | 0.97-2.56   | 61%         |
| Feed Type          |              |          |        |        |             |
| Balanced feed      | 27           | 176      | 203    | 0.14b  | 0.08-0.26   | 12%         |
| Mixed / homemade food| 14          | 14       | 28     | 7.05a  | 3.81-13.04  | 88%         |
| Reproductive state |              |          |        |        |             |
| Intact             | 32           | 130      | 162    | 1.47c  | 0.68-3.16   | 60%         |
| Spayed             | 7            | 66       | 73     | 0.68c  | 0.32-1.47   | 40%         |

Meaning: a. Risk factor, statistically significant; b. Protection factor, statistically significant; c. Not significant
DISCUSSION

**General prevalence.** Females and males diagnosed with tumor lesions accounted for 63.8% and 36.8%, respectively, which agrees with a previous study (32) reporting 58% lesions for females and 39% for males. We found that alterations of the mammary gland are the most frequent cause of consultation (1,5,12,13,33,34,35).

**Prevalence by age, breed, and body condition.** The prevalence of CMT was higher in purebreds, consistent with the results of other studies (9,10,23,24,35). Medium-sized and small breeds are more frequently diagnosed with CMT than large breeds (10,35). French Poodle is the most common among the purebreds, a finding that agrees with previous studies conducted in the same city (36) and other cities of Colombia (12,13). Cocker Spaniel and Beagle also show high prevalence (10). For large breeds, Labrador Retriever, Golden Retriever, and German
Shepherd were the most reported \((9,11,12,32)\). The presence of CMT and its frequency in certain breeds greatly depends on the popularity of the breeds, degree of ownership, and trends for certain breeds in a given area. For this reason, no general tendency was observed. However, in small breeds, an earlier diagnosis of tumor alterations is more frequent since these breeds are more easily managed by their owners.

The mean age was 9.3 years with a higher prevalence between 10 and 12 years old. Our findings agree with previous studies \((11,36,37)\) and with age ranges reported by different authors, 9-11 years old \((4,20)\), 6-10 years \((9,35)\), 7-11.9 years \((33)\), 10-11.9 years \((34)\), 8-11 years \((32)\), and 8-10 years \((13)\). In particular, six years old is known as the “age of cancer” \((1,15,19)\). Furthermore, the incidence of the disease increases with age, with maximum peaks between 9 and 10 years old \((1,35)\) and decreases around 12 years old. Another peak is observed at approximately 13 years old and there are also exceptional cases before 5 years old. The age of 10 in canine females is considered equivalent to 58 in women, and these are the mean ages of cancer presentation in both groups \((38)\).

**Clinical aspects and prevalence.** The inguinal pairs (pair 5) were the most diagnosed with CMT \((16.9\%)\). Several findings indicate that pairs 4-5 were the most susceptible to CMT presentation \((7,10,37)\). CMT is less frequent in the cranial thoracic glands. The affected area can involve a single gland \((10)\) or the inguinal and cranial glands simultaneously \((24)\). The patients showed greater compromise of the left side \((7)\), but these findings differ from other studies \((e.g., 9)\). Conventionally, the size of the mammary glands tends to decrease from the cranial to the caudal; in particular, the thoracic glands are the smallest, the abdominal glands are intermediate, and the inguinal are the largest. However, tumor presentation depends on other factors as well, including a change in the lymphatic drainage pattern through lymphangiogenesis during CMT development \((39)\).

The diameters T1 and T3 were the most frequent, although we did not find patterns for diameter or clinical stage that indicated a dominance of any \((13,35)\) since both displayed relatively similar percentages of presentation for the patterns of metastasis, LN or distant \((7)\).

Among benign tumors, we mainly found tumors of epithelial origin such as benign mixed tumors, complex adenomas, fibroadenomas, and papillary adenomas \((11)\). The most frequently diagnosed malignant tumors of epithelial origin were carcinoma in mixed tumor, tubular carcinoma and, papillary carcinoma. Other authors have also reported these tumors as the most prevalent \((12)\). Inflammatory lesions can be confused with tumor alterations \((40)\). Histopathologically, mammary inflammations are characterized by mononuclear and mixed infiltrates. Small and hard masses are usually benign, while large masses that tend to ulcerate are generally malignant \((9)\). The survival rate is favored by surgical intervention \((7,17)\), yet it can also be affected by other factors.

This study provides an update of the epidemiological variables of CMT and discusses the risk factors that affect the development of the disease. The findings are highly relevant considering the importance of canines as sentinels for CMT in humans. We identify the need and opportunity of continuing to develop epidemiological studies that correlate environmental factors with patterns of CMT occurrence. Furthermore, the registration, management, and definitive histopathological diagnosis of mammary neoplasia must be improved. This can be achieved by optimizing and integrating medical record storage systems to enable data management and analysis at the population level. Unless this is accomplished, it will be difficult to determine the real impact of CMT on public health.

**Conflict of Interests**

The authors declare that there are no conflicts.

**Acknowledgments**

To the Vicerrectoría de Investigaciones y Posgrados, Universidad de Caldas, for providing funding for the research projects titled “Expresión de los genes ER-A, MUC1, HER-2, y su significancia en el diagnóstico temprano en cáncer mamario canino en Manizales, Caldas” Code. 0298218, and “Sensores biocompatibles basados en nanoestructuras de oro y plata para el diagnóstico de cáncer de mama” Code. 0923517 of the grant “Convocatoria Conjunta para el Fomento de la Investigación Aplicada y Desarrollo Tecnológico” between the Universidad de Caldas and Universidad Nacional de Colombia - Sede Manizales. To the Ethics Committee for Animal Experimentation-CEEA-Cód. 15061601. To Dr. Etna Julieth Giraldo Pinzón for her support in monitoring patients. Finally, to the Veterinary Care Centers of the city of Manizales and its metropolitan area.
REFERENCES

1. Dhami MA, Tank PH, Karle AS, Vedpathak HS, Bhatia AS. Epidemiology of canine mammary gland tumours in Gujarat. Veterinary World. 2010; 3(6):282–285. URL: http://www.veterinaryworld.org/Vol.3/June/Epidemiology%20of%20Canine%20Mammary%20Gland%20Tumours%20in%20Gujarat.pdf

2. Pinho SS, Carvalho S, Cabral J, Reis CA, Gärtner, F. Canine tumors: A spontaneous animal model of human carcinogenesis. Transl Res. 2012; 159(3):165–172. https://doi.org/10.1016/j.trsl.2011.11.005

3. Dobson JM. Breed-Predispositions to Cancer in Pedigree Dogs. ISRN Vet Sci. 2013; 2013:941275. http://dx.doi.org/10.1155/2013/941275

4. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G, Bocchini, V. Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med. 2008; 22(4):976–984. https://doi.org/10.1111/j.1939-1676.2008.0133.x

5. Vascellari M, Baioni E, Ru G, Carminato A, Mutinelli F. Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. BMC Vet Res. 2009; 5(39):1-9. https://doi.org/10.1186/1746-6148-5-39

6. Kumaraguruparan R, Karunagaran D, Balachandran C, Manohar BM, Nagini S. Of humans and canines: a comparative evaluation of heat shock and apoptosis-associated proteins in mammary tumors. Clin Chim Acta. 2006; 365(1-2):168-176. https://doi.org/10.1016/j.cca.2005.08.018

7. Chang SC, Chang CC, Chang TJ, Wong ML. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). J Am Vet Med Assoc. 2005; 227(10):1625-1629. https://doi.org/10.2460/javma.2005.227.1625

8. Sleeckx N, de Rooster H, Veldhuis KE, Van Ginneken C, Van Brantegem L. Canine Mammary Tumours, an Overview. Reprod Domest Anim. 2011; 46(6):1112–1131. https://doi.org/10.1111/j.1439-0531.2011.01816.x

9. Hemanth I, Kumar R, Varshney KC, Nair MG, Ramesh KB, Sivakumar M, Thanillass J. Epidemiological and clinical studies on canine mammary tumors. Indian J Vet Res. 2015; 24(1):11-14. https://www.indianjournals.com/ijor.aspx?target=ijor;ijvr&volume=24&issue=1&article=003

10. Sahabi K, Selvarajah GT, Noordin MM, Sharma RSK, Dhaliwal GK. Retrospective Histopathological Study of Canine Mammary Gland Tumours Diagnosed From 2006 – 2012 in University Putra Malaysia. J Vet Malaysia. 2015; 27(1):1–6. http://jvm.vam.org.my/wp-content/uploads/2016/07/JVM-2015-Issue-1_Karibu.pdf

11. Salas Y, Márquez A, Díaz D, Romero L. Epidemiological Study of Mammary Tumors in Female Dogs Diagnosed during the Period 2002-2012: A Growing Animal Health Problem. PLoS One. 2015; 10:e0127381. https://doi.org/10.1371/journal.pone.0127381

12. Bravo TD, Cruz-Casallas P, Ochoa AJ. Prevalencia de neoplasias en caninos en la universidad de los Llanos, durante 2004 a 2007. Rev MVZ Córdoba. 2010; 15(1):1925-1937. https://doi.org/10.21897/mvz.330

13. Caicedo JA, Iregui CA, Cabarcas ME, Acosta BJ. Estudio comparativo de la frecuencia de tumores mamarios según sexo, edad y tipo histológico en caninos y humanos en los laboratorios de patología anatómica de la Universidad Nacional de Colombia sede Bogotá. Rev Col Cien Anim. 2012; 5(1):52-66. http://revistas.ut.edu.co/index.php/ciencianimal/article/view/124/123
14. Hsu WL, Huang HM, Liao JW, Wong ML, Chang SC. Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. Vet J. 2009; 180(1):116–123. https://doi.org/10.1016/j.tvjl.2007.10.013

15. Shinoda H, Legare ME, Mason GL, Berkbigler JL, Afzali MF, Flint AF, Hanneman WH. Significance of ERα, HER2, and CAV1 expression and molecular subtype classification to canine mammary gland tumor. J Vet Diagn Invest. 2014; 26(3):390–403. https://doi.org/10.1177/1040638714527289

16. Campos, LC, Silva JO, Santos FE, Araújo MR, Lavalle GE, Ferreira E, Cassali GD. Prognostic significance of tissue and serum HER2 and MUC1 in canine mammary cancer. J Vet Diag Inv. 2015; 27(4):531–535. https://doi.org/10.1177/1040638715592445

17. Sorenmo KU, Rasotto R, Zappulli V, Goldschmidt MH. Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. Vet Pathol. 2011; 48(1):85–97. https://doi.org/10.1177/0300985810389480

18. Rao NAS. Characterization of Canine Mammary Carcinoma using Dog-Specific cDNA arrays, [Ph.D. Thesis]. Utrecht University. Faculty of Veterinary Medicine: Holland, Utrecht; 2008. https://dspace.library.uu.nl/bitstream/1874/27479/2/nagesharao.pdf

19. Perez-Alenza MD, Peña L, Del Castillo N, Nieto, AI. Factors influencing the incidence and prognosis of canine mammary tumours. J Small Anim Pract. 2000; 41(7):287–291. https://doi.org/10.1111/j.1748-5827.2000.tb03203.x

20. Texeira SV, Silva ILD, Nunes FC, Campos CB, Oliveira MR, Lavalle GE, Cassali GD. Serum evaluation of leptin, IL-6, IGF-1 and estrogen in obese bitches with early stages of mammary carcinoma. Arq Bras Med Vet Zootec. 2019. 71(1):143-150. http://dx.doi.org/10.1590/1678-4162-10259

21. Youlden DR, Cramb SM, Dunn NAM, Muller JM, Pyke CM, Baade P D. The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Canc Epid. 2012; 36(3):237–248. https://doi.org/10.1016/j.canep.2012.02.007

22. Vogel VG. Epidemiology of Breast Cancer, In: Bland KI, Copeland EM, Klimberg VS, Gradishar WJ, (editors). The Breast, Comprehensive Management of Benign and Malignant Diseases. 5th ed. United States: Elsevier; 2018. URL: https://www.us elsevierhealth.com/the-breast-9780323359559.html

23. Vascellari M, Capello K, Carminato A, Zanardello C, Baioni E, Mutinelli F. Incidence of mammary tumors in the canine population living in the Veneto region (Northeastern Italy): Risk factors and similarities to human breast cancer. Prev Vet Med. 2016; 126(1):183–189. https://doi.org/10.1016/j.prevetmed.2016.02.008

24. Dias MLM, Leon AJM, Castro MB, Galera PD. Survival analysis of female dogs with mammary tumors after mastectomy: epidemiological, clinical and morphological aspects. Pesq. Vet. Bras. 2016; 36(3):181-186. http://dx.doi.org/10.1590/S0100-736X2016000300006

25. Salt C, Morris PJ, German AJ, Wilson D, Lund EM, Cole TJ, Butterwick RF. Growth standard charts for monitoring bodyweight in dogs of different sizes. PLoS ONE. 2017; 12(9):1-28. https://doi.org/10.1371/journal.pone.0182064

26. Fritz, A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S, editors. International Classification of Diseases for Oncology. 3rd ed. Switzerland: World Health Organization; 2013, https://apps.who.int/iris/bitstream/handle/10665/96612/9789241548496_eng.pdf;jsessionid=CCF9BE0DE27A782CE3591EBBC2FC85?sequence=1

27. Laflamme DP. Understanding and Managing Obesity in Dogs and Cats. Vet Clin Small Anim. 2006; 36(6):1283–1295. https://doi.org/10.1016/j.cvsm.2006.08.005
28. Simpson JW, Anderson RS, Markwell PJ, editors. Clinical Nutrition of Dog and Cat. United Kingdom: Blackwell Scientific; 1993. https://www.cabdirect.org/cabdirect/abstract/19931461684

29. Neto GBP, Brunetto MA, Sousa MG, Carciofi AC, Camacho AA. Effects of weight loss on the cardiac parameters of obese dogs. Pesq Vet Bras. 2010; 30(2):167-171. http://dx.doi.org/10.1590/S0100-736X2010000200012

30. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. United States: Springer; 2010. https://cancerstaging.org/references-tools/deskreferences/Documents/AJCC%207th%20Ed%20Cancer%20Staging%20Manual.pdf

31. Cassali GD, Lavalle GE, Brunner CH, Ferreira EJ, Bertagnolli AC, Lima AE, et al. Consensus for the Diagnosis, Prognosis and Treatment of Canine Mammary Tumors. Braz J Vet Pat. 2011; 4(2):153-180. https://bjvp.org.br/wp-content/uploads/2015/07/DOWNLOAD-FULL-ARTICLE-29-20881_2011_7_11_14_42.pdf

32. de la Cruz HNI, Monreal GAE, Carvajal FV, Barrón VCA, Martínez BJ, Zarate TA, et al. Frecuencia y caracterización de las principales neoplasias presentes en el perro doméstico en Tamaulipas (México). Rev Med Vet. 2017; 35:53-71. http://dx.doi.org/10.19052/mv.4389

33. Gal AF, Andriopoulou A, Miclăuş V, Tăbăran F, Taulescu M, Nagy A, et al. Comparative Data Concerning the Incidence of Tumors in Dogs in a Period of Ten Years in Athens (Greece) and Cluj-Napoca (Romania) Bull. UASVM Vet Med. 2015; 72(2):371-377. http://dx.doi.org/10.15835/mbasymcvm-vm:11538

34. Baioni E, Scanziani E, Vincenti MC, Leschiera M, Bozzetta E, Pezzolato M, et al. Estimating canine cancer incidence: findings from a population-based tumour registry in northwestern Italy. BMC Vet Res. 2017; 13(203):1-9. https://doi.org/10.1186/s12917-017-1126-0

35. Pastor N, Caballé NC, Santella M, Ezquerra LJ, Tarazona, R, Duran E. Epidemiological study of canine mammary tumors: age, breed, size and malignancy. Austral J Vet Sci. 2018; 50(3):143-147. https://doi.org/10.4067/S0719-8132218000300143

36. Pedraza-Ordoñez FJ, Ferreira De-La-Cuesta G, Murillo Mnejura SM. Análisis retrospectivo de 124 casos de neoplasia mamaria en caninos de la ciudad de Manizales. Revista Veterinaria y Zootecnia. 2008; 2(2):21-28. http://vip.ucaldes.edu.co/vetzootec/downloads/v2n2a02.pdf

37. Gupta K, Kumar NS, Kumar, SU, Mohindroo J, Mahajan S, Raghunath M, Singh K. Epidemiological studies on canine mammary tumour and its relevance for breast cancer studies. IOSR J Phar. 2012; 2(2):322-333. http://iosrphr.org/papers/v2i2/ZJ022322333.pdf

38. Scheneider R, Dorn CR, Taylor, DON. Factors Influencing Canine Mammary Cancer Development and Postsurgical Survival. JNat Cancer Inst. 1969; 43(6):1249-1261. https://doi.org/10.1093/jnci/43.6.1249

39. Patsikas MN, Karayannopoulou M, Kaldrymidoy E, Papazoglou LG, Papadopoulou PL, Tzegas SI, et al. The lymph drainage of the neoplastic mammary glands in the bitch: a lymphographic study. Anat Histol Embryol. 2006; 35(4):228-234. https://doi.org/10.1111/j.1439-0264.2005.00664.x

40. Boerkamp KM, Teske E, Boon LR, Grinwis CMG, Van den Bossche L, Rutteman GR. Estimated incidence rate and distribution of tumours in 4,653 cases of archival submissions derived from the Dutch golden retriever population. BMC Vet Res. 2014; 10(34):1-10. https://doi.org/10.1186/1746-6148-10-34